Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.
$8.69-1.25%
报价 2026-11-13
市值
$7.35B
EV
–
PE (TTM)
15.2x
预期 PE
–
52 周区间距高点 -10.6%
$7.02$9.72
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - General| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GRFSGrifols, S.A. | $7.35B | -1.3% | – | 38.4% | 15.2x | 10.0x | – | |
| GILDGilead Sciences, Inc. | $208.48B | +0.1% | +7.2% | 81.1% | 20.0x | 14.5x | 14.9x | |
| NVONovo Nordisk A/S | $183.52B | +2.4% | – | 78.2% | 10.3x | 7.2x | – | Cheap |
| PFEPfizer Inc. | $164.67B | +0.2% | +1.7% | 72.8% | 37.3x | 17.7x | 14.7x | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $129.66B | +1.8% | +4.6% | 67.7% | 16.5x | 10.5x | 14.0x | |
| SNYSanofi | $116.66B | -0.2% | – | 71.7% | 8.9x | 9.7x | – | |
| GSKGSK plc | $101.41B | +0.5% | – | 72.5% | 13.7x | 7.8x | – | |
| BIIBBiogen Inc. | $37.46B | +1.2% | +7.9% | 70.5% | 20.8x | 10.0x | 16.0x | |
| OGNOrganon & Co. | $3.65B | 0.0% | -1.4% | 53.1% | 14.2x | 8.0x | 5.4x | Cheap |
| 同行中位数 | – | – | +4.6% | 72.1% | 15.4x | 9.8x | 14.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 EUR(非美元)暂无季度数据(首次研究运行后填充)。